Literature DB >> 34905179

CD48-expressing non-small-cell lung cancer cells are susceptible to natural killer cell-mediated cytotoxicity.

Eun Jae Park1, Hye Won Jun1, Ik Ho Na1, Hong Kyung Lee1, Jieun Yun2, Hyung Sook Kim3, Youngsoo Kim1, Jin Tae Hong1, Sang-Bae Han4.   

Abstract

The susceptibility of cancer cells to natural killer (NK) cell-mediated cytotoxicity depends on the balance of activating and inhibitory ligands expressed on their surface. Although many types of cancer cells are killed by NK cells, non-small-cell lung cancer (NSCLC) cells are relatively resistant to NK cell-mediated cytotoxicity. In this study, we showed that several NSCLC cell lines have differential sensitivity to NK cell-mediated cytotoxicity: NCI-H522 cells were highly sensitive, but A549, NCI-H23, NCI-H1915, and NCI-H1299 were resistant. Among activating ligands such as CD48, HLA-A/B/G, ICAM-1, MICA/B, and ULBPs, only CD48 rendered NCI-H522 cells susceptible to NK cell-mediated cytotoxicity, which was proved by using CD48 siRNA and neutralizing antibody. CD48-positive NCI-H522 cells established a more stable contact with NK cells than did CD48-negative A549 and CD48 siRNA cell-transfected NCI-H522 cells. Taken together, these data demonstrate that CD48-positive NSCLC cells might be susceptible to NK cell-mediated cytotoxicity, which provide information on how to stratify NSCLC patients potentially responsive to NK-cell therapy.
© 2021. The Pharmaceutical Society of Korea.

Entities:  

Keywords:  CD48; Contact stability; NK-cell therapy; NSCLC; Susceptibility

Mesh:

Substances:

Year:  2021        PMID: 34905179     DOI: 10.1007/s12272-021-01365-z

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  44 in total

1.  The Immunological Genome Project: networks of gene expression in immune cells.

Authors:  Tracy S P Heng; Michio W Painter
Journal:  Nat Immunol       Date:  2008-10       Impact factor: 25.606

2.  2B4 engagement mediates rapid LFA-1 and actin-dependent NK cell adhesion to tumor cells as measured by single cell force spectroscopy.

Authors:  Sabrina C Hoffmann; André Cohnen; Thomas Ludwig; Carsten Watzl
Journal:  J Immunol       Date:  2011-01-26       Impact factor: 5.422

3.  A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells.

Authors:  B A Garni-Wagner; A Purohit; P A Mathew; M Bennett; V Kumar
Journal:  J Immunol       Date:  1993-07-01       Impact factor: 5.422

Review 4.  Natural killer cell biology: an update and future directions.

Authors:  Kerry S Campbell; Jun Hasegawa
Journal:  J Allergy Clin Immunol       Date:  2013-07-30       Impact factor: 10.793

5.  Molecular basis of the dual functions of 2B4 (CD244).

Authors:  Lukasz K Chlewicki; C Alejandro Velikovsky; Vamsi Balakrishnan; Roy A Mariuzza; Vinay Kumar
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

6.  Modulation of natural killer cell functions by interactions between 2B4 and CD48 in cis and in trans.

Authors:  Maren Claus; Sabine Wingert; Carsten Watzl
Journal:  Open Biol       Date:  2016-05-25       Impact factor: 6.411

Review 7.  Natural Killer Cells: Development, Maturation, and Clinical Utilization.

Authors:  Alex M Abel; Chao Yang; Monica S Thakar; Subramaniam Malarkannan
Journal:  Front Immunol       Date:  2018-08-13       Impact factor: 7.561

8.  2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48.

Authors:  M H Brown; K Boles; P A van der Merwe; V Kumar; P A Mathew; A N Barclay
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

9.  A soluble multimeric recombinant CD2 protein identifies CD48 as a low affinity ligand for human CD2: divergence of CD2 ligands during the evolution of humans and mice.

Authors:  A R Arulanandam; P Moingeon; M F Concino; M A Recny; K Kato; H Yagita; S Koyasu; E L Reinherz
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

Review 10.  The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy.

Authors:  Gerhard Hamilton; Adelina Plangger
Journal:  Biologics       Date:  2021-07-07
View more
  1 in total

1.  Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes.

Authors:  Chang-Keun Cho; Hye-Jung Park; Pureum Kang; Sungmin Moon; Yun Jeong Lee; Jung-Woo Bae; Choon-Gon Jang; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2021-11-22       Impact factor: 4.946

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.